Dermatological adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex

Br J Dermatol. 2020 Sep;183(3):588-589. doi: 10.1111/bjd.19124. Epub 2020 May 26.

Authors

D J Pithadia^{1

2}, A M Treichel^{1

2}, A M Jones², P Julien-Williams², T Machado², J Moss², T N Darling¹

Affiliations

¹ Department of Dermatology, Uniformed Services University, Bethesda, MD, USA.
² Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Cohort Studies
Humans
Mechanistic Target of Rapamycin Complex 1
Sirolimus / adverse effects
TOR Serine-Threonine Kinases
Tuberous Sclerosis Complex 2 Protein
Tuberous Sclerosis* / drug therapy

Substances

Tuberous Sclerosis Complex 2 Protein
Mechanistic Target of Rapamycin Complex 1
TOR Serine-Threonine Kinases
Sirolimus

Grants and funding